Abstract: The present invention relates to a modified release pharmaceutical formulation comprising one or more sustained release granules that may be prepared by over-mixing and hot melt granulation. The invention also relates to disintegrating monolithic modified release tablets comprising the sustained release granules as an internal phase and an immediate release formulation of a drug or drugs as an external phase. The drug release profile from either these granules or these tables may be adjusted by adjusting the percentages of the formulation's components. In one application, the disintegrating monolithic modified release tablets comprise amoxicillin and clavulanate and have a dissolution profile similar to brand and generic “Augmentin XR® Bilayered Extended Release Tablets (1000 mg/62.5 mg)”. The invention also relates to a method of preparing the foregoing sustained release granules.

Abstract: The present invention relates to a modified release pharmaceutical formulation comprising one or more sustained release granules that may be prepared by over-mixing and hot melt granulation. The invention also relates to disintegrating monolithic modified release tablets comprising the sustained release granules as an internal phase and an immediate release formulation of a drug or drugs as an external phase. The drug release profile from either these granules or these tables may be adjusted by adjusting the percentages of the formulation's components. In one application, the disintegrating monolithic modified release tablets comprise amoxicillin and clavulanate and have a dissolution profile similar to brand and generic “Augmentin XR® Bilayered Extended Release Tablets (1000 mg/62.5 mg)”. The invention also relates to a method of preparing the foregoing sustained release granules.

Abstract: The invention relates to a standard solution for inverse gas chromatography and/or surface energy analysis; a volumetric container for preparing such a standard solution; a method of preparing such a standard solution for inverse gas chromatography and/or a surface energy analysis and a method of probing a solid sample. The standard solution comprises a series of three or more compounds of increasing carbon chain length of general formula (I): R—X wherein: for the three or more compounds R is a series of alkyl, a series of alkenyl or a series of alkynyl groups of increasing carbon chain length; and for all three or more compounds X is H, OH, CO2H, C(O)H, C(O)CH3, NH2, SH or halogen; and the relationship between carbon chain length and volume of the compounds of increasing carbon chain length of general formula (I) is determined by the following formula.

Abstract: The invention relates to a standard solution for inverse gas chromatography and/or surface energy analysis; a volumetric container for preparing such a standard solution; a method of preparing such a standard solution for inverse gas chromatography and/or a surface energy analysis and a method of probing a solid sample. The standard solution comprises a series of three or more compounds of increasing carbon chain length of general formula (I): R—X wherein: for the three or more compounds R is a series of alkyl, a series of alkenyl or a series of alkynyl groups of increasing carbon chain length; and for all three or more compounds X is H, OH, CO2H, C(O)H, C(O)CH3, NH2, SH or halogen; and the relationship between carbon chain length and volume of the compounds of increasing carbon chain length of general formula (I) is determined by the following formula.

Abstract: The present invention relates to a modified release pharmaceutical formulation comprising one or more sustained release granules that may be prepared by over-mixing and hot melt granulation. The invention also relates to disintegrating monolithic modified release tablets comprising the sustained release granules as an internal phase and an immediate release formulation of a drug or drugs as an external phase. The drug release profile from either these granules or these tables may be adjusted by adjusting the percentages of the formulation's components. In one application, the disintegrating monolithic modified release tablets comprise amoxicillin and clavulanate and have a dissolution profile similar to brand and generic “Augmentin XR® Bilayered Extended Release Tablets (1000 mg/62.5 mg)”. The invention also relates to a method of preparing the foregoing sustained release granules.